Idarubicina Sandoz (Idarubicin Hydrochloride)

Idarubicin is an anthracycline chemotherapy indicated for acute leukemias, where it acts on rapidly dividing malignant cells.

• Acute Myeloid Leukemia (AML): induces remission by intercalating into DNA, inhibiting topoisomerase II and triggering apoptosis of leukemic blasts, thereby improving response rates in induction therapy.
• Acute Lymphoblastic Leukemia (ALL): contributes to disease control in adult patients with high‑risk or relapsed disease by causing irreversible DNA strand breaks and enhancing cytotoxic effects of combination regimens.
• Acute leukemia (general): employed in induction protocols to achieve rapid cytoreduction and facilitate subsequent consolidation therapy.

• Idarubicin exerts its antineoplastic activity by intercalating between DNA base pairs, which disrupts the double‑helix structure and prevents replication. It also stabilizes the DNA‑topoisomerase II complex, inhibiting the enzyme’s ability to reseal DNA strands after cleavage, leading to accumulation of double‑strand breaks. In addition, the anthracycline core generates free radicals that cause oxidative damage to cellular membranes and organelles, collectively resulting in apoptosis of rapidly dividing cancer cells.

Idarubicin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly observed during treatment.
• Alopecia: reversible hair loss affecting scalp and body hair.
• Myelosuppression: decreased blood cell counts leading to neutropenia, anemia and thrombocytopenia.
• Fatigue: generalized tiredness that may affect daily activities.

Serious or Rare Side Effects

• Cardiotoxicity: dose‑related decline in left ventricular function that may be irreversible.
• Severe infection: opportunistic infections due to profound neutropenia.
• Hemorrhage: bleeding complications from thrombocytopenia or coagulopathy.

When using Idarubicina Sandoz, clinicians should observe several precautionary measures to minimise risks.

• Cardiac monitoring: assess baseline and periodic left ventricular ejection fraction during therapy.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia, anemia or thrombocytopenia.
• Liver function: evaluate hepatic enzymes before and throughout treatment, adjusting dose if impairment occurs.
• Renal function: monitor serum creatinine and adjust dosing in cases of renal insufficiency.
• Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin may interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Concurrent anthracyclines: additive cardiotoxicity risk.
• Trastuzumab or other HER2‑targeted agents: synergistic heart damage.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may raise idarubicin levels, requiring dose adjustment.
• CYP3A4 inducers (e.g., rifampin): may reduce efficacy by lowering drug exposure.
• Radiation therapy: combined use can enhance bone marrow suppression.
• Anticoagulants: increased bleeding risk due to thrombocytopenia.